# Effectiveness and Safety of Dabrafenib in Combination With Trametinib as Adjuvant Treatment for Chinese Patients With Stage III BRAF V600 Mutation-positive Melanoma After Complete Resection

> **NCT04666272** · — · ACTIVE_NOT_RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 78 (actual)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** dabrafenib
- **DRUG:** trametinib

## Key facts

- **NCT ID:** NCT04666272
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-12-31
- **Primary completion:** 2028-02-04
- **Final completion:** 2028-02-04
- **Target enrollment:** 78 (ACTUAL)
- **Last updated:** 2026-02-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04666272

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04666272, "Effectiveness and Safety of Dabrafenib in Combination With Trametinib as Adjuvant Treatment for Chinese Patients With Stage III BRAF V600 Mutation-positive Melanoma After Complete Resection". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04666272. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*